Keller Rohrback Announces Ongoing Investigation of Claims Against KaloBios Pharmaceuticals, Inc.
Keller Rohrback announces that it is investigating claims of potential misrepresentations by KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased or otherwise acquired KaloBios shares and would like more information regarding the investigation, we advise you to contact Juli Farris or Rebecca Heneghen to discuss your rights without cost to you. You can reach us at 800-776-6044, or by email at info@KellerRohrback.com.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the December 17, 2015, arrest of Martin Shkreli for securities fraud. He is being accused of using Retrophin Inc.’s stock, a company Shkreli founded in 2011, to pay off hedge fund debts from unrelated business dealings.
If you have any questions concerning your legal rights in this case, please immediately contact Rebecca Heneghen at 800-776-6044, or visit our website at www.krcomplexlit.com, or email us at info@Kellerrohrback.com.
Keller Rohrback L.L.P. represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.